Bullish
Pfizer's LITFULO shows significant repigmentation in vitiligo patients.
Pfizer's LITFULO (ritlecitinib) demonstrated significant improvement in facial and total body repigmentation in patients with nonsegmental vitiligo, according to results from two Phase 3 trials. This positive outcome may enhance the company's position in dermatology.
Key points
- LITFULO's Phase 3 trials show significant repigmentation in vitiligo patients.
Sources
AI-generated from public news sources. Not financial advice.
